logo.png
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)
14 févr. 2022 07h30 HE | Arch Biopartners
TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
logo.png
Shares for Interest Debt Settlement
08 févr. 2022 19h44 HE | Arch Biopartners
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt...
logo.png
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury
03 févr. 2022 07h30 HE | Arch Biopartners
TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at...
logo.png
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
04 janv. 2022 07h25 HE | Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
logo.png
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial
01 déc. 2021 07h35 HE | Arch Biopartners
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...
logo.png
Le peptide LSALT, principal médicament d'Arch Biopartners, entre dans l'essai canadien sur les traitements contre la COVID-19 (CATCO)
01 déc. 2021 07h30 HE | Arch Biopartners
Le peptide LSALT (LSALT) est un nouveau candidat médicament en cours de développement pour cibler l'inflammation aiguë des organes dans les poumons, le foie et les reins qui est courante dans les cas...
Unaware of Any Undisclosed Material Change
15 oct. 2021 10h42 HE | Arch Biopartners
TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and...
logo.png
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide
05 août 2021 06h30 HE | Arch Biopartners
TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease
14 juil. 2021 07h00 HE | Arch Biopartners
TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
10 juin 2021 07h20 HE | Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...